AlphAIAlphAI — Financial news for AI agents
gurufocus.comAUG 262 min read$ZYME

ZYME Looks 47.1% Overvalued on GF Value™

Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.

Original reporting
gurufocus.com
Published Aug 26, 2026, 4:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 5:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ZYME
Bullish
high confidence
Mentioned
$ZYME
Relevance
9/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ZYMEBullishHigh
01

Why it matters

The $250 M milestone provides near‑term liquidity and validates the commercial potential of Ziihera, likely supporting the stock’s momentum.

02

Market read

Regulatory approval creates a clear catalyst for ZYME and may influence peer biotech valuations.

03

What to watch

Insider selling and guru trimming suggest caution; future milestone payments depend on commercial success of Ziihera.

Relevance 9/10Novelty 9/10Timing: same‑day release on August 26 2026

Background

Zymeworks is a clinical‑stage biotech that licenses its assets; the FDA approval validates its partnership strategy.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

FDA approval of two Ziihera regimens triggered a $250 million milestone payment and an 8% share surge.

Expected impact

short‑term bullish pressure; potential continuation if commercialization proceeds.

Evidence & confidence

The approval is a primary, material event with a sizable cash infusion and immediate price reaction.

Market effects

Sector

Biotech sector may see heightened interest in licensing deals and FDA‑driven catalysts.

Regional

North American biotech indices could receive a modest lift.

Global

Limited to companies with similar partnership models; no broad macro effect.

Counterpoint

What could challenge this read

High valuation multiples (P/S ≈ 60x) and ongoing cash‑flow negativity could limit upside despite the payment.

Key entities

  • company
    Zymeworks Inc

    Clinical‑stage biotech receiving FDA approval for partnered regimens.

  • company
    Jazz Pharmaceuticals

    Licensee of Ziihera; responsible for the $250 M milestone payment.

Read at source← All news

Related articles

SEP 23
$ZYMEHighAI 8/10

Zymeworks Inc. (ZYME): Completion of Acquisition or Disposition of Assets

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portf

SEC EDGAR 8-K2 min
SEP 8
$ZYMEMedAI 8/10

Zymeworks at Wells Fargo conference: cash flow, zanidatamab drive

Zymeworks (ZYME) presented at the Wells Fargo Healthcare Conference, highlighting its strategy focused on zanidatamab, royalty income, and acquisitions. Zanidatamab received FDA approval for gastric cancer, with Jazz Pharmaceuticals raising its peak sales estimate to $3B-$5B. Zymeworks raised $600M in debt, repurchased 10.5M shares, and plans to acquire Theravance Respiratory. Management expects profitability in 2026, with analysts forecasting 34% upside.

investing.com3 min
AUG 26
$ZYMEHighAI 9/10

FDA approves new indications for Ziihera

Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.

thepharmaletter.com2 min
AUG 26
$ZYMEHighAI 9/10

H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval

H.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.

investing.com2 min
AUG 25
$ZYMEHighAI 8/10

Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab

Zymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.

yahoo.com2 min